Terminated PHASE3 INTERVENTIONAL 2-arm NCT00737282

Multicenter Study Evaluating the Safety of Proellex® in Premenopausal Women With Uterine Fibroids

A Phase III, Open-Label, Parallel, Randomized, Multicenter Study Evaluating the Safety of 25 And 50 mg Proellex® (CDB-4124) in the Treatment of Premenopausal Women With Symptomatic Uterine Fibroids

Sponsor: Repros Therapeutics Inc.

Conditions Uterine Fibroids

Interventions Proellex 25 mg Proellex 50 mg

Updated 7 times since 2017 Last updated: Aug 5, 2014 Started: Oct 31, 2008 Primary completion: Aug 31, 2009 Completion: Aug 31, 2009

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

Terminated

Repros stopped study for safety and FDA put study on hold.

Other terminated trials from Repros Therapeutics Inc.

More terminations from Repros Therapeutics Inc.

Other Uterine Fibroids trials with similar outcome

Browse all Uterine Fibroids trials

Listed as NCT00737282, this PHASE3 trial focuses on Uterine Fibroids and remains terminated or withdrawn. Sponsored by Repros Therapeutics Inc., it has been updated 7 times since 2008, reflecting limited change activity. This study adds to the evidence base for this therapeutic area through structured, versioned documentation.

Status Flow

Change History

7 versions recorded

Sep 2024 — Present [monthly]

Terminated PHASE3
Jul 2024 — Sep 2024 [monthly]

Terminated PHASE3
Dec 2021 — Jul 2024 [monthly]

Terminated PHASE3
Jan 2021 — Dec 2021 [monthly]

Terminated PHASE3
Jun 2018 — Jan 2021 [monthly]

Terminated PHASE3

▶ Show 2 earlier versions

Feb 2017 — Jun 2018 [monthly]

Terminated PHASE3
Jan 2017 — Feb 2017 [monthly]

Terminated PHASE3

First recorded

Oct 2008

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Repros Therapeutics Inc.

Data source: Repros Therapeutics Inc.

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

Ann Arbor, United States , Atlanta, United States , Austin, United States , Beverly Hills, United States , Decatur, United States , Eugene, United States , Fall River, United States , Grand Rapids, United States , Greenville, United States , Little Rock, United States and 10 more locations